Long acting risperidone in treatment of schizophrenia:A retrospective study
暂无分享,去创建一个
[1] S. Selek,et al. Atypical antipsychotics as “mood stabilizers”: A retrospective chart review , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[2] J. Kahn,et al. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone , 2007, International clinical psychopharmacology.
[3] S. Selek,et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. , 2007, Journal of affective disorders.
[4] J. Lindenmayer,et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder , 2007, European Neuropsychopharmacology.
[5] M. Valenstein,et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. , 2006, The Journal of clinical psychiatry.
[6] S. Selek,et al. Acute dystonia after initial doses of ziprasidone: A case report , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[7] J. Kane,et al. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection , 2005, Schizophrenia Research.
[8] J. Lauriello,et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia , 2005, Schizophrenia Research.
[9] B. Remmerie,et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia , 2004, Schizophrenia Research.
[10] R. Love,et al. Long-acting risperidone injection. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] J. Lindenmayer,et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. , 2004, The Journal of clinical psychiatry.
[12] M. Turner,et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone , 2004, European Psychiatry.
[13] G. Remington,et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. , 2003, The Journal of clinical psychiatry.
[14] S. Keith,et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. , 2003, The American journal of psychiatry.
[15] J. Lieberman,et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.
[16] M. Livingston,et al. Risperidone , 1994, The Lancet.
[17] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.